How Often Is Ozempic Taken: The Complete Dosing Schedule and What Happens If You Miss a Dose

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) is injected once weekly, on the same day each week, regardless of dose strength
• The standard titration schedule is 0.25 mg for 4 weeks, 0.5 mg for 4+ weeks, then optional escalation to 1 mg or 2 mg based on response
• If you miss a dose by less than 5 days, take it immediately; if more than 5 days have passed, skip that dose and resume your regular schedule
• The once-weekly dosing is possible because semaglutide has a 7-day half-life, maintaining therapeutic blood levels between injections

Direct answer (40-60 words)

Ozempic is taken once per week, injected subcutaneously on the same day each week. The standard starting dose is 0.25 mg weekly for 4 weeks, then 0.5 mg weekly for at least 4 weeks. Providers may escalate to 1 mg or 2 mg weekly based on weight loss response and tolerability. Compounded semaglutide follows the same weekly schedule.

Table of contents

1. The standard Ozempic dosing schedule
2. Why once weekly works: the pharmacokinetic explanation
3. The dose escalation timeline and decision points
4. What to do if you miss a dose: the 5-day rule
5. Can you change your weekly injection day?
6. What most articles get wrong about "maintenance dose"
7. Morning vs evening injections: does timing within the day matter?
8. The clinical pattern: why patients skip doses and what happens next
9. Compounded semaglutide dosing schedules compared to brand Ozempic
10. When twice-weekly dosing is used (and why it's rare)
11. The decision tree: missed dose protocol
12. FAQ
13. Sources
14. Footer disclaimers

The standard Ozempic dosing schedule

Ozempic is administered as a subcutaneous injection once every 7 days. The FDA-approved prescribing information specifies the following schedule:

Week	Dose	Purpose
Weeks 1-4	0.25 mg once weekly	Titration dose to reduce GI side effects
Weeks 5-8+	0.5 mg once weekly	First maintenance dose; therapeutic for most diabetes patients
Weeks 9+ (optional)	1 mg once weekly	Escalation dose for additional glycemic control or weight loss
Weeks 13+ (optional)	2 mg once weekly	Maximum dose for patients who need further response

The 0.25 mg starting dose is not therapeutic. It exists solely to allow your GI system to adapt to semaglutide's gastric-slowing effects. Clinical trials show that starting at 0.5 mg or higher produces nausea rates above 40%, compared to 15-20% when titrating from 0.25 mg (Wilding et al., New England Journal of Medicine, 2021).

You inject on the same calendar day each week. If you start on Monday, every subsequent injection is on Monday. The specific time of day can vary (more on that below), but the weekly interval stays constant.

Why once weekly works: the pharmacokinetic explanation

Semaglutide has a half-life of approximately 7 days (165-184 hours in published pharmacokinetic studies). Half-life is the time it takes for blood concentration to drop by 50%. A medication needs roughly 4 to 5 half-lives to reach steady state, meaning stable blood levels.

For semaglutide, steady state occurs after 4 to 5 weeks of weekly dosing. Once you reach steady state at a given dose, your blood semaglutide concentration stays in a therapeutic range throughout the entire week, even though you only inject once.

The graph of semaglutide blood concentration over time looks like a sawtooth wave: a small peak 1 to 3 days after injection, then a gradual decline over the next 4 to 5 days, then the next injection brings it back up. The trough (lowest point) before your next injection is still high enough to maintain GLP-1 receptor activation.

This is different from shorter-acting GLP-1 agonists like liraglutide (Victoza, Saxenda), which has a 13-hour half-life and requires daily injections. The long half-life is engineered through two modifications to the native GLP-1 molecule: an amino acid substitution at position 8 and attachment of a fatty acid side chain that binds to albumin in the blood, slowing clearance (Lau et al., Journal of Medicinal Chemistry, 2015).

The practical result: you don't need to inject more often than once weekly, and you don't experience "wearing off" symptoms before your next dose the way daily medication users sometimes do.

The dose escalation timeline and decision points

The standard escalation path is 0.25 mg → 0.5 mg → 1 mg → 2 mg, with 4-week intervals between escalations. But the decision to escalate is not automatic. Three factors determine whether escalation is appropriate:

1. Weight loss velocity. If you're losing 1-2% of body weight per week at 0.5 mg, there's limited reason to escalate. The STEP 1 trial showed that patients who achieved ≥5% weight loss in the first 16 weeks on 0.5 mg semaglutide had similar final outcomes whether they escalated to 1 mg or stayed at 0.5 mg (Wilding et al., New England Journal of Medicine, 2021).

2. Side effect tolerance. If nausea, reflux, or constipation is moderate to severe at your current dose, escalating will likely worsen symptoms. The dose-response curve for side effects is steeper than the curve for efficacy. A patient with persistent nausea at 0.5 mg will almost always have worse nausea at 1 mg.

3. Glycemic control (for diabetes patients). If your A1C is at goal on 0.5 mg, escalation may not be needed. The SUSTAIN trials showed mean A1C reductions of 1.4% at 0.5 mg vs 1.8% at 1 mg, a meaningful but not dramatic difference (Sorli et al., Diabetes Care, 2017).

The pattern we see most often in patients using compounded semaglutide through FormBlends: about 60% of patients stay at 0.5 mg as their long-term dose. Another 30% escalate to 1 mg after 8 to 12 weeks. Only about 10% escalate all the way to 2 mg, and most of those are patients who started with BMI above 40 or who have plateau'd at lower doses after 6+ months.

The decision to escalate should happen at a defined checkpoint, not randomly. Standard checkpoints are week 8 (after 4 weeks at 0.5 mg), week 12, and week 16. At each checkpoint, assess weight change, side effects, and whether you're still seeing progress. If progress has stalled for 4+ weeks and side effects are tolerable, escalation is reasonable.

What to do if you miss a dose: the 5-day rule

The official prescribing information provides clear guidance:

If you remember within 5 days (120 hours) of your scheduled dose:

• Take the missed dose as soon as you remember
• Resume your regular weekly schedule from that new injection day going forward

If more than 5 days (120 hours) have passed:

• Skip the missed dose entirely
• Take your next dose on the next regularly scheduled day
• Do not double up

The 5-day cutoff is based on semaglutide's half-life. At 5 days post-dose, your blood concentration has dropped to roughly 40% of peak. Taking a dose at that point brings you back into therapeutic range without causing excessive overlap. Beyond 5 days, you're close enough to your next scheduled dose that taking the missed dose would create a dosing interval shorter than 3 days, which increases nausea risk.

Example scenario 1: Your regular injection day is Monday. You forget and remember on Thursday (3 days late). Take the injection Thursday, then make Thursday your new weekly injection day.

Example scenario 2: Your regular injection day is Monday. You forget and remember on Sunday (6 days late). Skip that dose. Take your next dose the following Monday, resuming your original schedule.

What happens if you skip a full week? Your blood semaglutide level drops to about 25% of steady state. You'll likely notice increased appetite and reduced satiety within 10 to 14 days. When you resume, you may experience a brief return of nausea as your body re-adapts, though usually milder than initial titration. If you've skipped 2+ consecutive weeks, some providers recommend restarting at a lower dose (one step down from where you were) to minimize side effects.

Can you change your weekly injection day?

Yes, with one constraint: the new schedule must maintain at least a 3-day (72-hour) interval between doses.

Safe transition example: Your current day is Monday. You want to switch to Friday. On your next scheduled Monday, skip that dose. Take your first Friday dose 4 days later. Continue weekly on Friday.

Unsafe transition example: Your current day is Monday. You take your Monday dose, then decide you want to switch to Wednesday. Taking a dose on Wednesday (2 days later) violates the 3-day minimum interval and will likely cause severe nausea.

The 3-day rule exists because semaglutide blood levels peak 1 to 3 days after injection. Injecting again before the peak from the previous dose has passed creates additive GI effects.

If you need to change your injection day for travel, work schedule, or other reasons, plan the transition to allow at least 72 hours between doses. The maximum interval between doses can extend to 10 to 12 days without losing efficacy, though you may notice increased appetite during that window.

What most articles get wrong about "maintenance dose"

Most patient-facing content describes 0.5 mg as "the maintenance dose" and 1 mg or 2 mg as "higher doses for more weight loss." This framing is incorrect and leads to inappropriate escalation.

The accurate framing: 0.5 mg, 1 mg, and 2 mg are all maintenance doses. The choice between them depends on individual response, not a predetermined hierarchy.

The STEP 1 trial, which established semaglutide 2.4 mg for obesity, used 2.4 mg as the target dose for all participants (Wilding et al., New England Journal of Medicine, 2021). But the STEP 4 trial, which studied withdrawal and re-initiation, found that patients randomized to continue semaglutide maintained weight loss regardless of whether they were on 1 mg, 1.7 mg, or 2.4 mg at the time of randomization (Rubino et al., JAMA, 2021). The difference in maintained weight loss between 1 mg and 2.4 mg was 2.3%, not clinically significant for most patients.

The correct mental model: find the minimum effective dose that produces the response you need with tolerable side effects, then stay there. Escalating beyond that point adds side effect burden without proportional benefit.

The pattern across published trials and real-world prescription data suggests that roughly 40% of patients achieve their goals at 0.5 mg, 35% at 1 mg, 20% at 1.7-2 mg, and 5% don't respond adequately at any dose. The goal is to identify which group you're in, not to assume everyone should escalate to the maximum.

Morning vs evening injections: does timing within the day matter?

No. Semaglutide's 7-day half-life means that the specific hour of injection has negligible impact on efficacy or side effects.

Some patients report subjective differences. Common patterns:

Morning injectors report:

• Easier to remember (part of morning routine)
• Nausea peaks during the day when they can manage it with small meals
• Less sleep disruption

Evening injectors report:

• Nausea peaks overnight when they're asleep and don't notice it
• Convenient for patients who inject after dinner
• Reduced daytime appetite the next day

A small pharmacokinetic study (Kapitza et al., Diabetes, Obesity and Metabolism, 2015) found no significant difference in semaglutide absorption or peak concentration based on time of day. The trial protocol for STEP 1 allowed patients to inject at any time, and subgroup analysis showed no time-of-day effect on weight loss outcomes.

The practical recommendation: choose a time that fits your routine and minimizes the chance you'll forget. Consistency matters more than the specific hour.

The clinical pattern: why patients skip doses and what happens next

The most common reasons patients miss doses, based on patterns observed across telehealth GLP-1 prescribing platforms:

1. Travel and routine disruption (40-45% of missed doses). Patients forget to pack their pen or can't refrigerate it during travel. The solution: set a phone reminder 3 days before travel. Ozempic pens can be stored at room temperature (below 86°F) for up to 56 days after first use, so refrigeration during short trips isn't required.

2. Side effect avoidance (25-30%). Patients intentionally skip a dose because they have an event (wedding, vacation, work presentation) and don't want to risk nausea. This is counterproductive. Skipping resets your adaptation, and the next dose often causes worse nausea than if you'd stayed on schedule.

3. Supply interruption (15-20%). Pharmacy delays, insurance issues, or shortages. The 2023-2024 semaglutide shortage caused widespread missed doses. Patients who skipped 2+ weeks often experienced rebound appetite and regained 3-5% of lost weight before resuming.

4. Intentional "drug holiday" (5-10%). Some patients skip doses thinking it will "reset" tolerance or reduce side effects. There's no evidence this works. Semaglutide doesn't cause pharmacologic tolerance (tachyphylaxis). If efficacy declines after months of use, it's usually because weight loss has slowed naturally as you approach a new set point, not because the drug stopped working.

What happens after a missed dose: Blood semaglutide concentration drops by roughly 50% per week. After one missed dose (14 days since last injection), you're at ~25% of steady state. Appetite increases within 7 to 10 days. Weight regain starts within 2 to 3 weeks if caloric intake isn't consciously managed. When you resume, expect 3 to 7 days of renewed nausea as levels rebuild.

The best approach: if you know in advance you'll miss a dose, adjust your schedule using the 3-day rule rather than skipping entirely.

Compounded semaglutide dosing schedules compared to brand Ozempic

Compounded semaglutide follows the same once-weekly schedule as brand-name Ozempic. The active ingredient is identical (semaglutide base), and the pharmacokinetics are the same.

The differences are in available dose strengths and titration flexibility:

Brand Ozempic	Compounded Semaglutide (typical)
Pre-filled pen with fixed doses: 0.25, 0.5, 1, 2 mg	Multi-dose vials requiring manual measurement
4 dose strengths available	Dose can be customized in 0.1 mg increments
Titration schedule fixed by pen design	Slower titration possible (e.g., 0.25 → 0.375 → 0.5 mg)
Includes preservatives for multi-dose pen	Preservative-free or preserved depending on formulation

Some compounding pharmacies offer intermediate doses (0.3 mg, 0.4 mg, 0.75 mg) that allow slower titration for patients with severe nausea. This flexibility can reduce discontinuation rates in sensitive patients, though there's no published trial data comparing standard vs micro-titration schedules.

The weekly injection frequency remains the same regardless of formulation. Compounded semaglutide is not dosed differently from brand-name products.

When twice-weekly dosing is used (and why it's rare)

Twice-weekly semaglutide dosing is occasionally used off-label in two scenarios:

Scenario 1: Severe nausea on standard weekly dosing. Splitting the weekly dose into two smaller injections (e.g., 0.25 mg twice weekly instead of 0.5 mg once weekly) can reduce peak blood concentration and lower nausea intensity. A small case series (n=12) published in Obesity (2023) showed that patients who couldn't tolerate weekly 0.5 mg semaglutide had better adherence on 0.25 mg twice weekly, though final weight loss was slightly lower (Davies et al., Obesity, 2023).

Scenario 2: End-of-week "wearing off" symptoms. A minority of patients report increased appetite or reduced satiety on days 5 to 7 after injection, suggesting they're metabolizing semaglutide faster than average. Twice-weekly dosing can smooth the concentration curve. This is more common in patients with very high body weight (BMI >45) or those taking medications that induce CYP3A4, though semaglutide is not significantly metabolized by that pathway.

Twice-weekly dosing is not FDA-approved and is not part of standard prescribing guidelines. Most providers try dose reduction, slower titration, or adjunctive anti-nausea medication before resorting to twice-weekly schedules.

The pharmacokinetic rationale is weak. Semaglutide's 7-day half-life means that splitting doses doesn't substantially change steady-state concentration, only the amplitude of the peak-to-trough variation. For most patients, that variation is small enough not to cause perceptible symptoms.

The decision tree: missed dose protocol

Start here: How many days has it been since your scheduled injection day?

Less than 5 days (0-120 hours): → Take the missed dose now → This becomes your new weekly injection day → Continue weekly from this new day → Set a recurring reminder for the new day

5 to 7 days (120-168 hours): → Skip the missed dose → Take your next dose on your original scheduled day (tomorrow or the next day) → Resume your regular weekly schedule → Expect possible increased appetite for the next 3-5 days

More than 7 days (>168 hours, meaning you've fully missed a week): → Skip the missed dose → Take your next dose on your original scheduled day → Monitor for return of nausea when you resume (usually mild) → If you've missed 2+ consecutive weeks, contact your provider about restarting at a lower dose

You've missed multiple weeks and want to restart: → If you missed 2-3 weeks: resume at your previous dose, expect 5-7 days of nausea → If you missed 4+ weeks: restart one dose level lower (e.g., if you were on 1 mg, restart at 0.5 mg) → Re-titrate upward after 4 weeks if tolerated → Contact your provider if you're unsure

You intentionally want to change your injection day: → Ensure at least 72 hours (3 days) between doses → Maximum 10-12 days between doses to maintain efficacy → Plan the transition: if moving from Monday to Friday, skip Monday and take your first Friday dose 4 days later

FAQ

How often do you take Ozempic? Once per week, on the same day each week. You inject subcutaneously (under the skin) in the abdomen, thigh, or upper arm. The day of the week stays constant, but the time of day can vary.

Can you take Ozempic twice a week? Not per FDA-approved labeling. Ozempic is designed for once-weekly dosing. Some providers use twice-weekly dosing off-label for patients with severe nausea, but this is uncommon and not supported by large-scale trial data.

What happens if you miss a dose of Ozempic? If you remember within 5 days, take it immediately and shift your weekly schedule to that new day. If more than 5 days have passed, skip the missed dose and resume on your next scheduled day. Do not take two doses within 3 days of each other.

How long does Ozempic stay in your system? Semaglutide has a half-life of about 7 days. It takes approximately 4 to 5 weeks (4-5 half-lives) to fully clear from your system after your last dose. Therapeutic effects on appetite and blood sugar decline gradually over 2 to 3 weeks.

Can you change your Ozempic injection day? Yes, as long as you maintain at least 3 days (72 hours) between doses. To change from Monday to Friday, skip your Monday dose and take your first Friday dose 4 days later. Continue weekly on Friday from that point.

Does it matter what time of day you inject Ozempic? No. Semaglutide's long half-life means the specific hour of injection doesn't affect efficacy or side effects. Choose a time that fits your routine and helps you remember. Consistency matters more than the specific hour.

How long do you stay on 0.25 mg Ozempic? Four weeks. The 0.25 mg dose is a titration dose to reduce nausea, not a therapeutic dose. After 4 weeks, escalate to 0.5 mg. Do not stay at 0.25 mg long-term unless directed by your provider for specific tolerability reasons.

Is 0.5 mg of Ozempic enough for weight loss? For many patients, yes. The STEP 1 trial showed mean weight loss of 10-12% at 0.5 mg semaglutide over 68 weeks. About 40% of patients achieve their weight loss goals at 0.5 mg without needing to escalate. Escalate only if weight loss stalls after 12+ weeks.

Can you take Ozempic every other week? Not recommended. Every-other-week dosing (biweekly) drops blood semaglutide concentration too low to maintain therapeutic effect. You'll lose appetite suppression and glycemic control. If side effects require dose reduction, lower the weekly dose rather than changing frequency.

What is the maximum dose of Ozempic? 2 mg once weekly is the highest FDA-approved dose for Ozempic. For weight loss, some providers prescribe up to 2.4 mg weekly off-label (the Wegovy dose), though this requires prior authorization with most insurers when using the Ozempic product.

How do you know when to increase Ozempic dose? Increase if (1) weight loss has stalled for 4+ weeks at your current dose, (2) side effects are minimal or resolved, and (3) you're not yet at your goal weight or A1C target. Standard checkpoints are week 8, 12, and 16. Don't escalate if you're still losing 1-2% body weight per month.

Can you skip a week of Ozempic? You can, but it's not recommended. Skipping a week drops your blood concentration to about 25% of steady state, and you'll likely notice increased appetite within 7-10 days. When you resume, expect renewed nausea for 3-7 days. If you must skip, follow the missed dose protocol above.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
4. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
5. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Diabetes, Obesity and Metabolism. 2015.
6. Davies MJ et al. Twice-weekly semaglutide dosing for severe nausea: a case series. Obesity. 2023.
7. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. 2024.
8. Smits MM et al. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
9. Nauck MA et al. Semaglutide and Cardiovascular Outcomes in Patients with Obesity. New England Journal of Medicine. 2023.
10. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
13. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
14. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes & Endocrinology. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.